S

AN FRANCISCO — Celgene (CELG) did not buy Bluebird Bio (BLUE). Instead, it said Sunday that it was purchasing a private company developing a me-too myelofibrosis drug with safety issues that, if approved, will need to fight for patients with an entrenched and well-regarded competitor.

It’s only a slight exaggeration to say investors gathered here were expecting to stream into the J.P. Morgan Healthcare conference Monday morning giddy with news of blockbuster biotech M&A. Celgene’s acquisition of Impact Biomedicines for $1.1 billion up front — and up to $7 billion total if all regulatory and sales milestones are are met — is not that deal.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

X